- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/40 - Oxygen atoms
Patent holdings for IPC class C07D 211/40
Total number of patents in this class: 122
10-year publication summary
|
5
|
8
|
8
|
7
|
5
|
5
|
8
|
12
|
5
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| FMC Corporation | 813 |
5 |
| ChemoCentryx, Inc. | 370 |
4 |
| Theravance Biopharma R&D IP, LLC | 425 |
4 |
| AstraZeneca AB | 2837 |
3 |
| Amgen Inc. | 4353 |
3 |
| Vividion Therapeutics, Inc. | 41 |
3 |
| Bristol-myers Squibb Company | 4812 |
2 |
| F. Hoffmann-La Roche AG | 7839 |
2 |
| Board of Regents, The University of Texas System | 6045 |
2 |
| ABAC Therapeutics S.L. | 7 |
2 |
| Amyris, Inc. | 365 |
2 |
| Athenex, Inc. | 25 |
2 |
| Neurocrine Biosciences, Inc. | 448 |
2 |
| Nippon Soda Co., Ltd. | 883 |
2 |
| Sirna Therapeutics, Inc. | 102 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2971 |
2 |
| Idorsia Pharmaceuticals Ltd. | 332 |
2 |
| Shanghai Meiyue Biotech Development Co., Ltd. | 57 |
2 |
| Shanghai Meizer Pharmaceuticals Co., Ltd. | 13 |
2 |
| ReNAgade Therapeutics Management Inc. | 56 |
2 |
| Other owners | 72 |